RxDoctor Payments Data

Stacey Hastreiter

Nurse Practitioner · Gillette, WYNPI 1225324668

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $564 of the $764 with a category attached, or 73.7%. 10 manufacturers reported payments, led by Merck at 24.8% of the total.

$764in general payments, 2019–2025

Across 37 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$190
  • Seagen Inc.$185
  • Pfizer$115
  • Daiichi Sankyo Inc.$90
  • Amgen$75
  • Pharmacyclics LLC, An Abbvie Company$32
  • plus $78 from 4 others

What the payments were for

  • Food & beverage$56474%
  • Education$20126%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$764 in reported general payments places this provider in the 85th percentile of 150 nurse practitioner providers in Wyoming.

See all nurse practitioner providers in Wyoming

Medicare billing

Part B allowed, 2024
$44,614
Medicare patients
190
Services billed
483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib12$194,900
JakafiRuxolitinib Phosphate11$183,896
Lenalidomide12$182,228
Abiraterone Acetate37$53,733
EliquisApixaban15$9,133
Anastrozole66$1,133
Letrozole40$835
Oxycodone Hcl47$732
Morphine Sulfate ErMorphine Sulfate20$712
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen30$677
Acyclovir26$628
Dexamethasone27$558
Gabapentin22$438
Hydroxyurea22$417
Ondansetron Hcl25$246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$32$194,90012 claims
PfizerEliquis$115$9,13315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 150 nurse practitioner providers in Wyoming.

Other nurse practitioner in Gillette

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →